Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tigeliflozin
- Development stage
- Phase 2
- Lead developer
- Tianjin Institute of Pharmaceutical Research
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tigeliflozin is an orally active, small molecule sodium-glucose cotransporter 2 (SGLT2) inhibitor developed by the Tianjin Institute of Pharmaceutical Research for the treatment of type 2 diabetes mellitus. By selectively inhibiting SGLT2 in the proximal convoluted tubules of the kidney, tigeliflozin reduces the reabsorption of filtered glucose and lowers the renal threshold for glucose. This mechanism promotes urinary glucose excretion (glucosuria) and reduces plasma glucose levels in an insulin-independent manner, which also provides secondary benefits such as modest weight loss and blood pressure reduction. It has been investigated in clinical trials in China to evaluate its safety, tolerability, and pharmacokinetic profile.
- Other names
- tigeliflozin L-proline
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on tigeliflozin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tigeliflozin.